Skip Navigation

A Phase III Randomized Trial of Pembrolizumab in Combination with Sacituzumab Govitecan vs Standard of Care in Anti-PDL1-Resistant Advanced Urothelial Cancer

Brief Summary

Type:
Bladder

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT06524544

Study #:
STUDY00162332

Start Date:
Mar 30, 2026

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06524544

View Complete Trial Details & Eligibility at ClinicalTrials.gov